Author:
Svoboda Roman,Nevyhoštěná Marie,Macháčková Jana,Vaculík Jan,Knotková Kateřina,Chromčíková Maria,Komersová Alena
Abstract
Abstract
Purpose
Affinisol HPMC HME is a new popular form of hypromellose specifically designed for the hot melt extrusion and 3D printing of pharmaceutical products. However, reports of its thermal stability include only data obtained under inert N2 atmosphere, which is not consistent with the common pharmaceutical practice. Therefore, detailed investigation of its real-life thermal stability in air is paramount for identification of potential risks and limitations during its high-temperature processing.
Methods
In this work, the Affinisol HPMC HME 15LV powder as well as extruded filaments will be investigated by means of thermogravimetry, differential scanning calorimetry and infrared spectroscopy with respect to its thermal stability.
Results
The decomposition in N2 was proceeded in accordance with the literature data and manufacturer’s specifications: onset at ~260°C at 0.5°C·min−1, single-step mass loss of 90–95%. However, in laboratory or industrial practice, high-temperature processing is performed in the air, where oxidation-induced degradation drastically changes. The thermogravimetric mass loss in air proceeded in three stages: ~ 5% mass loss with onset at 150°C, ~ 70% mass loss at 200°C, and ~ 15% mass loss at 380°C. Diffusion of O2 into the Affinisol material was identified as the rate-determining step.
Conclusion
For extrusion temperatures ≥170°C, Affinisol exhibits a significant degree of degradation within the 5 min extruder retention time. Hot melt extrusion of pure Affinisol can be comfortably performed below this temperature. Utilization of plasticizers may be necessary for safe 3D printing.
Funder
Ministerstvo Školství, Mládeže a Tělovýchovy
Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
Agentúra na Podporu Výskumu a Vývoja
University of Pardubice
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference60 articles.
1. Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009;8(3):203–12.
2. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603–16.
3. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11–22.
4. Pudipeddi M, Serajuddin ATM, Mufson D. Integrated drug product development—from lead candidate selection to life-cycle management. The Process of New Drug Discovery and Development. Boca Raton: CRC Press; 2006.
5. Li S, He H, Parthiban LJ, Yin H, Serajuddin ATM. IV-IVC considerations in the development of immediate-release oral dosage form. J Pharm Sci. 2005;94(7):1396–417.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献